Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer.
Takahashi S, Sakamoto Y, Denda T, Takashima A, Komatsu Y, Nakamura M, Ohori H, Yamaguchi T, Kobayashi Y, Baba H, Kotake M, Amagai K, Kondo H, Shimada K, Sato A, Yuki S, Okita A, Ouchi K, Komine K, Watanabe M, Morita S, Ishioka C. Takahashi S, et al. Among authors: ohori h. Cancer Sci. 2021 Apr;112(4):1567-1578. doi: 10.1111/cas.14841. Epub 2021 Feb 27. Cancer Sci. 2021. PMID: 33548159 Free PMC article. Clinical Trial.
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, Nakamura M, Yamaguchi T, Ohori H, Kobayashi K, Tsuda M, Kobayashi Y, Miyamoto Y, Kotake M, Shimada K, Sato A, Morita S, Takahashi S, Komatsu Y, Ishioka C. Yamada Y, et al. Among authors: ohori h. Ann Oncol. 2018 Mar 1;29(3):624-631. doi: 10.1093/annonc/mdx816. Ann Oncol. 2018. PMID: 29293874 Free PMC article. Clinical Trial.
Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers.
Takahashi M, Sakamoto Y, Ohori H, Tsuji Y, Kuroki M, Kato S, Otsuka K, Komine K, Takahashi M, Takahashi S, Shirota H, Ouchi K, Takahashi Y, Imai H, Shibata H, Yoshioka T, Tanaka M, Yamaguchi H, Yamaguchi T, Shimodaira H, Ishioka C. Takahashi M, et al. Among authors: ohori h. Cancer Chemother Pharmacol. 2021 Sep;88(3):393-402. doi: 10.1007/s00280-021-04277-3. Epub 2021 May 24. Cancer Chemother Pharmacol. 2021. PMID: 34028598 Free PMC article. Clinical Trial.
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.
Denda T, Takashima A, Gamoh M, Iwanaga I, Komatsu Y, Takahashi M, Nakamura M, Ohori H, Sakashita A, Tsuda M, Kobayashi Y, Baba H, Kotake M, Ishioka C, Yamada Y, Sato A, Yuki S, Morita S, Takahashi S, Yamaguchi T, Shimada K. Denda T, et al. Among authors: ohori h. Eur J Cancer. 2021 Sep;154:296-306. doi: 10.1016/j.ejca.2021.06.013. Epub 2021 Jul 22. Eur J Cancer. 2021. PMID: 34304054 Free article. Clinical Trial.
Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study.
Kato S, Imai H, Gamoh M, Takahata T, Ohori H, Yasuda K, Niitani T, Murakawa Y, Amagai K, Isobe H, Shindo Y, Kuroki M, Sakamoto Y, Shimodaira H, Yoshioka T, Ishioka C. Kato S, et al. Among authors: ohori h. Tohoku J Exp Med. 2018 May;245(1):21-28. doi: 10.1620/tjem.245.21. Tohoku J Exp Med. 2018. PMID: 29743448 Free article. Clinical Trial.
Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis.
Okita A, Imai H, Takahashi M, Takahashi H, Umegaki S, Kawamura Y, Hiraide S, Ouchi K, Sato Y, Okada Y, Komine K, Saijo K, Takahashi S, Takahashi M, Shirota H, Ohori H, Gamoh M, Ishioka C. Okita A, et al. Among authors: ohori h. Tohoku J Exp Med. 2018 Jun;245(2):123-129. doi: 10.1620/tjem.245.123. Tohoku J Exp Med. 2018. PMID: 29937450 Free article.
Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203).
Takahashi M, Sakamoto Y, Otsuka K, Kanbe M, Ohori H, Shindo Y, Honda H, Saijo K, Ouchi K, Murakawa Y, Takahashi H, Kawai S, Tanaka Y, Yamaguchi T, Shimodaira H, Yoshioka T, Ishioka C. Takahashi M, et al. Among authors: ohori h. Tohoku J Exp Med. 2021 May;254(1):49-55. doi: 10.1620/tjem.254.49. Tohoku J Exp Med. 2021. PMID: 34053967 Free article. Clinical Trial.
Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial.
Yoshioka T, Takahashi M, Sakamoto Y, Okita A, Fukui T, Murakawa Y, Shindo Y, Imai H, Ohori H, Shirota H, Chiba N, Sasahara YI, Nomura T, Fukushima N, Yamaguchi T, Shimodaira H, Ishioka C. Yoshioka T, et al. Among authors: ohori h. Anticancer Res. 2022 Apr;42(4):2009-2015. doi: 10.21873/anticanres.15680. Anticancer Res. 2022. PMID: 35347022 Clinical Trial.
76 results